Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


China to Step Up Inspection of Fish Farms in Crackdown on Illegal Use of Drugs, Chemicals (China)

This article was originally published in PharmAsia News

Executive Summary

China will inspect fish farms across the country to guard against the use of illegal drugs and chemicals, a move that was made as a team of U.S. health officials met with Chinese officials to discuss stepping up controls on two-way food and drug exports and increasing cooperation. Besides inspections, the new measures also include the blacklisting of violators and better education and training for producers. U.S. Treasury Secretary Henry Paulson, who ended two days of trade talks with Chinese leaders in Beijing, said his discussions touched on consumer product safety and food safety but he gave no details. China's lucrative but lightly regulated pharmaceutical industry has also been under stricter surveillance. The former head of China's State Food and Drug Administration was executed in June for taking bribes and gifts in exchange for approving substandard medications for the domestic market, including an antibiotic blamed in the deaths of at least 10 people. China's drug watchdog has suspended sales of two batches of a leukemia drug that was under investigation after users reported adverse reactions including leg pains and difficulty walking. Shanghai Pharmaceutical (Group) Co., China's biggest drug-maker and the parent company of the unit that made the methotrexate, has said it was investigating the problem. (Click here for more - May Require Free Registration

You may also be interested in...

QUOTED. 18 September 2020. Ed Israelski.

The US FDA has been skeptical about remote testing, but independent consultant (and former Abbott human factors director) Ed Israelski predicts the pandemic may bring a change.

US Bill Urges Automatic Insulin Interchangeability

A draft Biosimilar Insulin Access Act, intended to waive US interchangeability requirements for FDA-approved biosimilar insulins, has been introduced by representative Glenn Grothman.

Ex-Cipla Executive To Helm JB Chemicals

The former CEO of Cipla’s India business is set to steer JB Chemicals and Pharmaceuticals, as the Indian firm embarks on a new phase of growth, backed by a revamped board, following its takeover by US private equity firm KKR.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts